Original language | English |
---|---|
Pages (from-to) | e221-e223 |
Journal | Journal of the European Academy of Dermatology and Venereology |
Volume | 35 |
Issue number | 3 |
Early online date | 13 Sep 2020 |
DOIs | |
Publication status | Published - Mar 2021 |
Access to Document
- 10.1111/jdv.16941Licence: CC BY
- An approach for the transition from systemic immunosuppressants to dupilumabFinal published version, 367 KBLicence: CC BY
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
An approach for the transition from systemic immunosuppressants to dupilumab. / de Wijs, L. E.M.; Thyssen, J. P.; Vestergaard, C. et al.
In: Journal of the European Academy of Dermatology and Venereology, Vol. 35, No. 3, 03.2021, p. e221-e223.Research output: Contribution to journal › Article › Professional › peer-review
TY - JOUR
T1 - An approach for the transition from systemic immunosuppressants to dupilumab
AU - de Wijs, L. E.M.
AU - Thyssen, J. P.
AU - Vestergaard, C.
AU - Thio, H. B.
AU - Kunkeler, A. C.M.
AU - Biedermann, T.
AU - Hijnen, D. J.
N1 - Funding Information: L.E.M. de Wijs, H.B. Thio and A.C.M. Kunkeler have none to declare. J.P. Thyssen attended advisory boards for Eli Lilly, Regeneron, Pfizer, LEO Pharma, AbbVie and Sanofi Genzyme; received speaker honorarium from LEO Pharma, AbbVie, Regeneron and Sanofi Genzyme; and received research grants from Regeneron and Sanofi Genzyme. C. Vestergaard has acted as speaker and/or investigator for Sanofi Genzyme, AbbVie, LEO Pharma, Galapagos, Pierre Fabre Dermo‐Cosmetique and Novartis. D.J. Hijnen has been an investigator for AbbVie, LEO Pharma, Galderma, MedImmune/AstraZeneca, Novartis and Sanofi/Regeneron; and consultant for Regeneron/Sanofi, LEO Pharma, MedImmune/AstraZeneca, Novartis, Incyte, Janssen, Pfizer and Lilly. T. Biedermann has been an institution investigator for AbbVie, LEO Pharma, Novartis, Sanofi/Regeneron, Janssen, Pfizer and Lilly; consultant for Alk‐Abelló, Mylan, Novartis and Sanofi/Regeneron; and received honorarium for talks or research grant from Alk‐Abelló, Celgene, Mylan, Novartis, Phadia/Thermo Fisher and Sanofi/Regeneron.
PY - 2021/3
Y1 - 2021/3
UR - http://www.scopus.com/inward/record.url?scp=85092197865&partnerID=8YFLogxK
U2 - 10.1111/jdv.16941
DO - 10.1111/jdv.16941
M3 - Article
C2 - 32920932
AN - SCOPUS:85092197865
VL - 35
SP - e221-e223
JO - Journal of the European Academy of Dermatology and Venereology
JF - Journal of the European Academy of Dermatology and Venereology
SN - 0926-9959
IS - 3
ER -